We are investigating Poseida Therapeutics, Inc. (PSTX) (“Poseida” or the “Company”) for potential violations of the federal securities laws. On or around July 10, 2020, Poseida completed its initial public offering (“IPO”), issuing 14 million shares of common stock priced at $16.00 per share. Then, on August 18, 2020, Poseida disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on Poseida’s Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer. The FDA placed the hold in order to investigate a patient death that occurred in late July. On this news, Poseida’s stock price fell $3.94 per share, or 30.31%, to close at $9.06 per share on August 18, 2020.